The normal functions of peptides that aggregate in Alzheimer’s, Parkinson’s, and Huntington’s have been largely overlooked by scientists, but some argue that they are critical for understanding the development of disease.
The Swiss Federal Institute of Technology Lausanne evolutionary neurobiologist is using Drosophila to investigate how organisms adapt to novel environments.
Personalized stem cells improved motor symptoms and depression signs in monkeys modeling Parkinson’s disease, paving the way for trials in human patients.
Making specific alterations to the bacterial population in a rat’s lungs either better protects the animals against multiple sclerosis–like symptoms or makes them more vulnerable, a study finds—the first demonstration of a lung-brain axis.
The University of Toronto and University of Vienna pharmacologist developed L-dopa, a precursor to dopamine that remains the most widely used therapy for Parkinson’s disease.
The BioCollective, a company that transforms whole stool samples into microbial metadata, is developing the US’s first national microbiome reference material.
The plant geneticist has revolutionized researchers’ understanding of how light affects plant growth and development, and is engineering plants to combat climate change.